Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

ESSENCE is a double-blinded, 240-week study that involves 1,200 adults with MASH and stage two or three liver fibrosis.

Bagsværd, Denmark Tuesday, November 5, 2024, 10:00 Hrs [IST] ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Endevica Bio has launched a new spin-off company, Abisati, to accelerate its obesity candidate into clinical trials.

Shares of Viking Therapeutics ($VKTX) surged nearly 25% in premarket trading on Monday after presenting promising early data on its oral obesity pill, VK2735, at the ...

Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with ...

Novo Nordisk's (NVO) semaglutide, marketed as Wegovy for obesity, shows promise in reducing joint disease symptoms in ...

UBS analyst Jo Walton maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,100.00. The ...